Release Date: 11/08/20 09:33 Summary: Letter from the Managing Director - FY'20 Price Sensitive: No Download Document 710.49KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%